Focus: Dyne Therapeutics is a public biotech company specializing in antibody-oligonucleotide conjugate treatments for rare muscle diseases, operating at mid-cap scale (~300 employees) from Waltham, MA.
Profile data last refreshed 11h ago · AI intelligence enriched 1w ago
Hot — 44 jobs added in 30d
Net +25 (44 new, 19 removed). Aggressive expansion phase.
Best suited for early-stage biotech specialists seeking differentiated science and commercial upside, but unsuitable for those prioritizing near-term revenue stability or established product expertise.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Dyne Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Dyne Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Royal Bank of Canada Buys 49,641 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Royal Bank of Canada Buys 49,641 Shares of Dyne Therapeutics, Inc. $DYN MarketBeat
Handelsbanken Fonder AB Acquires Shares of 53,200 Dyne Therapeutics, Inc. $DYN - MarketBeat
Handelsbanken Fonder AB Acquires Shares of 53,200 Dyne Therapeutics, Inc. $DYN MarketBeat
Flputnam Investment Management Co. Makes New Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Flputnam Investment Management Co. Makes New Investment in Dyne Therapeutics, Inc. $DYN MarketBeat
Aegis Wealth Management LLC Invests $3.33 Million in Dyne Therapeutics, Inc. $DYN - MarketBeat
Aegis Wealth Management LLC Invests $3.33 Million in Dyne Therapeutics, Inc. $DYN MarketBeat
Dyne Therapeutics (DYN) director's preset stock sale via Atlas funds - Stock Titan
Dyne Therapeutics (DYN) director's preset stock sale via Atlas funds Stock Titan
Dyne Therapeutics (NASDAQ: DYN) CCO sells shares to cover taxes - Stock Titan
Dyne Therapeutics (NASDAQ: DYN) CCO sells shares to cover taxes Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo